As reported by the Royal Pharmaceutical Society, five new UK research hubs, backed by £118 million in funding, will fast-track innovative health technologies for faster diagnoses and better treatments
A raft of new UK-created therapies for cancer will be trialled in the UK – furthering the nation’s life sciences industry as one of the great drivers of economic growth.
New partnerships backed by public and private sector investment will trial new ways to tackle cancer and other life-threatening diseases with faster diagnoses and better treatments, deploying innovative technologies and approaches.
It comes as UK Research and Innovation announces a £118 million fund that will create five new hubs across the country, from Glasgow to Bristol, to help develop new health technologies. The funding will be split between government funding and partner support – inviting business to help the mission to kickstart the economy and build an NHS fit for the future. T
The Hubs will work in intimate partnership with the private sector – with experts at UCL developing scanners to improve cancer surgery, delivering their research together with both large MedTech multinationals and British start-ups, for example.
Commenting on the UKRI Healthcare Research and Partnership Hubs, EPSRC Executive Chair Professor Charlotte Deane said: “The five new hubs bring together a wealth of expertise from across academia, industry and charities to improve population health, transform disease prediction and diagnosis, and accelerate the development of new interventions.
They represent an exciting range of adventurous techniques and approaches that have great potential to improve the lives of millions of people here in the UK and across the world.”